STAGE III PANCREATIC CANCER AJCC V8

This study tests a drug called M3814 (Peposertib) combined with a special type of radiation for people with locally advanced pancreatic cancer that has spread to nearby tissues. The goal is to find the safest dose and see if the combination helps stop tumor growth longer than rad…

This early-stage trial tests whether combining a targeted drug (olaparib), an immunotherapy (durvalumab), and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be surgically removed. About 18 participants will receive the combination after i…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…

This study tests whether giving a higher dose of radiation can help people with locally advanced pancreatic cancer live longer. Participants must have already had 4-6 months of chemotherapy. The trial compares higher-dose radiation to standard care (more chemo, observation, or lo…

This early-stage study tests a new chemotherapy drug, TR-002, in about 52 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. The study also looks at whether the drug can shr…

This early-phase trial tests whether adding leflunomide (an arthritis drug) to standard chemotherapy gemcitabine is safe and effective for people with advanced pancreatic cancer that cannot be removed by surgery. About 19 adults will receive the combination to find the best dose …

This study tests the drug talazoparib in adults with advanced solid tumors (like breast, prostate, ovarian, pancreatic, or stomach cancer) that have certain gene changes affecting DNA repair. The drug blocks a protein called PARP, which cancer cells need to fix their DNA, potenti…

This study tests a new combination for people with pancreatic cancer that cannot be surgically removed. It uses a light-activated drug (verteporfin) to make tumors more sensitive to immunotherapy (pembrolizumab) plus standard chemotherapy. The goal is to see if this approach shri…

This early-stage trial tests a new targeted drug (CA-4948) added to standard chemotherapy for people with pancreatic cancer that has spread or can't be removed. The goal is to find the safest dose and see if the combination can shrink tumors or slow the disease. About 43 adults w…

This study tests whether a simple, non-invasive acupressure technique on the ear can help improve appetite and prevent weight loss in people with advanced stomach, esophageal, or pancreatic cancer. About 66 participants will either receive the acupressure treatment or standard ca…

This study is for people with pancreatic cancer that can be removed by surgery or has spread. Researchers want to see how certain drugs affect tumor cells by comparing biopsies taken before and after treatment. The goal is to gather information to design better future studies, no…